

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) JUNE 10, 1996

ENZON, INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	0-12957 (Commission File Number)	22-237286 (IRS Employer Identification)
---	--	---

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY (Address of principal executive offices)	08854 (Zip Code)
---	---------------------

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") announced that it has exercised 150,000 warrants to purchase common stock of Neoprobe Corporation and sold the stock for a net profit of approximately \$1 million, after payment to Neoprobe of the aggregate average exercise price of \$10.50 per share. The warrants were part of the compensation Enzon received for licensing its Single-Chain Antigen-Binding (SCA(R)) protein technology to Neoprobe for use with Neoprobe's Radioimmunoguided Surgery (RIGS(R)) product under the license agreement originally signed in 1992. The warrants were due to expire in 1996. Enzon will also be entitled to receive additional payments per product upon the achievement of specified development milestones and royalties on sales of any future products developed by Neoprobe that utilize Enzon's SCA technology.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Dated: June 24, 1996

ENZON, INC.
(Registrant)

By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer